Dr. Agarwal's Health Care Limited (AGARWALEYE) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Dr. Agarwal's Health Care Limited enters its Q1 FY27 results following a landmark year where total income crossed the Rs. 2,000 crore mark. Investors will look for evidence that the company can sustain its ~21% revenue growth pace while managing the margin impact of its aggressive 60-facility expansion target for FY27.

Dr. Agarwal's Health Care Limited Q1 Results Date and Time

Board meeting scheduled for August 4, 2026 to consider Q1 FY27 unaudited results.

The earnings call is scheduled for August 4, 2026 at 5:30 PM IST.

What to expect from Dr. Agarwal's Health Care Limited's Q1 FY27 results

The company enters Q1 FY27 targeting a revenue growth pace similar to the 20.9% total income growth achieved in FY26, supported by a same-store sales growth trend that was north of 13.5% as of Q3 FY26. While Q4 FY26 EBITDA margins reached a peak of 30.2%, investors should anticipate a potential sequential dip toward the 28-29% range, consistent with the seasonal pattern observed in Q1 FY26 when margins were 28.2%. Management has guided for stable margins throughout FY27 despite an aggressive capex plan of Rs. 380-400 crore, relying on the faster ramp-up of new surgical centers and the higher ASPs driven by Femto cataract surgeries, which grew 87% YoY in FY26. The upcoming call will likely focus on whether the surgery volume growth of 14.5% seen in FY26 can be maintained as the company scales its network toward the 60-facility target for the current fiscal year.

Key Things To Watch

Performance vs. FY27 Guidance: Tracking the company's ability to maintain its growth trajectory and margin stability.

• Revenue growth pace: Monitoring if Q1 stays in line with the ~21% YoY growth target.
• EBITDA margin stability: Assessing if margins remain above the 28% level despite greenfield investment.
• New facility additions: Tracking progress against the 60-facility annual target (40 surgical, 20 clinics).

Merger and Regulatory Updates: Status of the AEHL amalgamation and GST compliance.

• NCLT final sanction timeline for the merger of Dr. Agarwal's Eye Hospital Ltd into AHCL.
• GST Show Cause Notice: Update on the Rs. 20.50 Cr demand and whether any provision has been recorded.

Operating Metrics and Capex: Key performance indicators driving operational leverage.

• Surgery growth rate: Evaluating if volume growth remains consistent with the 13.5-14% range.
• Capex deployment: Tracking Q1 spend against the full-year guidance of Rs. 380-400 Cr.
• Loss-making centers: Potential granularity on the ~Rs. 28 Cr losses previously flagged by management.